Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study

Journal Title: Annals of Hepatology - Year 2012, Vol 11, Issue 3

Abstract

Introduction. Hepatitis C virus genotype 4 is predominant in the Middle East and Northern Africa, even if it has recently spread to Southern Europe. Data about the treatment of post-liver transplantation (LT) genotype 4 hepatitis C recurrence are scarce. We report a retrospective analysis of post-LT genotype 4 hepatitis C treatment in 9 Italian transplant centres, focusing on the overall survival rates and treatment outcome. Results. Among 452 recipients, we identified 17 HCV genotype 4 patients (16 males, 1 female) transplanted between 1998 and 2007. All patients received combined antiviral treatment with conventional doses of interferon (recombinant or pegylated) and ribavirin after histological diagnosis of hepatitis C recurrence. The observed overall survival after LT was 100% at 1 year and 83.3% at 5 years. More than 1/3(35.3%) of patients achieved a sustained virological response (SVR) and 40% (data available in 15 subjects) an early virological response (EVR), which was significantly associated with the achievement of SVR (overall accuracy: 85.7%; predictive values of EVR absence/presence 80/88.8%; chi-square p < 0.05). Conclusion. In conclusion, in post-LT genotype 4 hepatitis C treatment, SVR rates are similar to genotype 1. Patients who don’t show an EVR are not likely to achieve a SVR.

Authors and Affiliations

Romana Francesca, Alessandro Milani, Antonio Gasbarrini, Raffaella Zaccaria, Maria Donato, Lucia Miglioresi, Luisa Pasulo, Daniele Paolo, Pierluigi Toniutto, Stefano Fagiuoli, Maurizio Pompili

Keywords

Related Articles

Sensitivity and Specificity of Biochemical Tests for Diagnosis of Intrahepatic Cholestasis of Pregnancy

Background and aim. Intrahepatic cholestasis of pregnancy (ICP) is linked with increased risk of fetal complications. An accurate diagnostic test is needed to diagnose this disorder on time. We aimed to assess sensitivit...

Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not relatedto interleukin-28B polymorphism

[b]Background and rationale[/b]. Age is one of the predictors for sustained virological response (SVR) when treating chronic hepatitis C (CHC) patients with pegylated-interferon/ribavirin (PegIFN/RBV). However, the treat...

Worldwide mortality from cirrhosis

Background/Aims: Cirrhosis mortality has registered large changes over the last few decades. Aim: To report worldwide mortality due to cirrhosis over the period 1980-2002. Methods: Age-standardized (world standard) cirrh...

Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin

Background and aims. Genetic variations in the interleukin 28B (IL28B) gene have been associated with viral response to PEG-interferon-α/ribavirin (PR) therapy in hepatitis C virus (HCV) genotype 1 infected patients from...

Download PDF file
  • EP ID EP78145
  • DOI -
  • Views 121
  • Downloads 0

How To Cite

Romana Francesca, Alessandro Milani, Antonio Gasbarrini, Raffaella Zaccaria, Maria Donato, Lucia Miglioresi, Luisa Pasulo, Daniele Paolo, Pierluigi Toniutto, Stefano Fagiuoli, Maurizio Pompili (2012). Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study . Annals of Hepatology, 11(3), 338-342. https://europub.co.uk/articles/-A-78145